1. Home
  2. GNTA vs IKNA Comparison

GNTA vs IKNA Comparison

Compare GNTA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNTA
  • IKNA
  • Stock Information
  • Founded
  • GNTA 2014
  • IKNA 2016
  • Country
  • GNTA Italy
  • IKNA United States
  • Employees
  • GNTA N/A
  • IKNA N/A
  • Industry
  • GNTA Biotechnology: Biological Products (No Diagnostic Substances)
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNTA Health Care
  • IKNA Health Care
  • Exchange
  • GNTA Nasdaq
  • IKNA Nasdaq
  • Market Cap
  • GNTA 67.4M
  • IKNA 83.0M
  • IPO Year
  • GNTA 2021
  • IKNA 2021
  • Fundamental
  • Price
  • GNTA $5.34
  • IKNA $1.68
  • Analyst Decision
  • GNTA Strong Buy
  • IKNA Buy
  • Analyst Count
  • GNTA 1
  • IKNA 2
  • Target Price
  • GNTA $25.00
  • IKNA $3.00
  • AVG Volume (30 Days)
  • GNTA 28.4K
  • IKNA 41.6K
  • Earning Date
  • GNTA 01-01-0001
  • IKNA 11-07-2024
  • Dividend Yield
  • GNTA N/A
  • IKNA N/A
  • EPS Growth
  • GNTA N/A
  • IKNA N/A
  • EPS
  • GNTA N/A
  • IKNA N/A
  • Revenue
  • GNTA N/A
  • IKNA $1,844,000.00
  • Revenue This Year
  • GNTA N/A
  • IKNA N/A
  • Revenue Next Year
  • GNTA N/A
  • IKNA N/A
  • P/E Ratio
  • GNTA N/A
  • IKNA N/A
  • Revenue Growth
  • GNTA N/A
  • IKNA N/A
  • 52 Week Low
  • GNTA $2.20
  • IKNA $1.02
  • 52 Week High
  • GNTA $7.28
  • IKNA $4.63
  • Technical
  • Relative Strength Index (RSI)
  • GNTA 56.89
  • IKNA 51.57
  • Support Level
  • GNTA $4.89
  • IKNA $1.68
  • Resistance Level
  • GNTA $6.20
  • IKNA $1.78
  • Average True Range (ATR)
  • GNTA 0.70
  • IKNA 0.04
  • MACD
  • GNTA -0.06
  • IKNA 0.00
  • Stochastic Oscillator
  • GNTA 37.32
  • IKNA 36.36

About GNTA Genenta Science S.p.A.

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: